We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
34
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Approved For Marketing
1
2.9%
Completed
24
70.6%
Terminated
4
11.8%
Withdrawn
5
14.7%
No approval data available
- ARS Pharmaceuticals achieved $32.5 million in Q3 2025 revenue, with $31.3 million from neffy U.S. sales, demonstrating continued commercial momentum for the first FDA-approved needle-free epinephrine treatment. - The company's direct-to-consumer campaign significantly boosted consumer awareness from 20% to 56% by September 2025, while over 18,000 healthcare providers have now prescribed neffy. - Real-world evidence from 680 patients showed approximately 90% effectiveness with a single neffy dose for anaphylaxis treatment, matching historical epinephrine injection outcomes. - Global expansion accelerated with neffy approvals in Japan and EUR neffy launches in Germany and the United Kingdom, establishing an international footprint for the needle-free epinephrine technology.
